When Jonathan Solomon first heard about a SPAC, he had no idea what it was. But now that the CEO has completed the first one in biotech, coming out with a fresh $61 million in financing while making the public flip to the New York Stock Exchange, he’s a convert to the cause.

To view the article – click : Here’s a new way to raise money for your biotech.